Growth factors during HCV therapy may be "cost-effective", but are they "effective"? (Q50574708)

From Wikidata

Jump to navigation Jump to search

scientific article published in December 2006

Language	Label	Description	Also known as
English	Growth factors during HCV therapy may be "cost-effective", but are they "effective"?	scientific article published in December 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

0 references

Growth factors during HCV therapy may be "cost-effective", but are they "effective"? (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

author name string

Andrew J Muir

1

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

John G McHutchison

2

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

language of work or name

0 references

publication date

1 December 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

44

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

6

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

1400-1403

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

American Gastroenterological Association technical review on the management of hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

American Gastroenterological Association medical position statement on the management of hepatitis C

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions

1 reference

https://api.crossref.org/works/10.1002%2FHEP.21426

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.21426

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 March 2018

http://europepmc.org/abstract/MED/17133467

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50574708&oldid=1458532242"